跳至主要内容
临床试验/CTRI/2025/07/091843
CTRI/2025/07/091843已完成Unknown

A Non-Randomized, Single Arm, Open Label, Multicentric Post Marketing Study to evaluate safety profile of FDC of Calcium Aspartate 1120 mg plus Magnesium Hydroxide 180 mg plus Vitamin D3 1000 IU film coated tablets in the treatment of Calcium and Vitamin D deficiency

OVERSEAS HEALTH CARE PVT LTD.4 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2025年8月15日最近更新:

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
200
试验地点
4
主要终点
To evaluate the safety of patients.

研究概览

简要总结

This is a non-randomized, single-arm, open-label, multicentric post-marketing study designed to evaluate the safety of a fixed-dose combination (FDC) of Calcium Aspartate 1120 mg, Magnesium Hydroxide 180 mg, and Vitamin D3 1000 IU film-coated tablets in adults with calcium and vitamin D deficiency. A total of 200 patients will be enrolled and administered the study product orally once daily for a duration of eight weeks.

The primary focus of the study is on safety assessment, which includes monitoring of adverse events, evaluation of patient well-being, and recording of any concomitant medications. Adult patients aged 18 years and above who are already using the study FDC and willing to provide informed consent are eligible to participate. Female participants of childbearing potential must have a negative pregnancy test and must agree to use highly effective contraception or maintain abstinence.

Exclusion criteria include hypersensitivity to any components of the study drug, history of severe allergic reactions, relevant medical conditions such as hepatic or renal impairment, hypercalcemia, and conditions like nephrolithiasis or Zollinger-Ellison syndrome. Patients requiring hormone or steroid therapy, those with a history of substance abuse, or those participating in another clinical study will also be excluded.

Subjects may be withdrawn from the study due to serious adverse events, protocol non-compliance, pregnancy, voluntary withdrawal of consent, or at the discretion of the investigator, Ethics Committee, or sponsor. All withdrawal reasons will be recorded, and in the case of serious adverse events, the relevant Ethics Committee and sponsor will be notified within 24 hours.

In conclusion, this FDC offers a well-balanced combination of calcium, magnesium, and vitamin D to support bone health and overall wellness. Its convenient single-tablet format enhances compliance and effectiveness in addressing common nutritional deficiencies.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 75.00 Year(s)(—)
性别
Female

入选标准

  • Adult patients age 18 years and above.
  • Patients those who are already administering this FDC before screening and willing to provide written informed consent form to participate in the study.
  • Patients must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits.
  • Female patients of childbearing potential must have a negative serum pregnancy report and should follow abstinence or use contraceptive methods with a failure rate of less than 1 percent.
  • Patient is eligible for or currently receiving treatment with calcium and vitamin D supplement.

排除标准

  • Hypersensitivity to Calcium and Vitamin D and other components of the study drugs.
  • History of severe allergic reactions or drug intolerance.
  • Other significant diseases, at the discretion of the investigator.
  • For non-pregnant Patients: lactating women, or women intending to become pregnant during the study.
  • Has a history of known fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.
  • Has a disease and or condition resulting in hypercalcaemia and or hypercalciuria and for which the study drugs are contraindicated e.g. Zollinger-Ellison syndrome, nephrolithiasis
  • Patients immediately require any surgical interventions for their bone and joint disease.
  • Patients taking or require Hormone therapy.
  • Patients taking steroidal therapy.
  • Abuse of alcohol or drugs.
  • Hepatic and Renal impairment.

结局指标

主要结局

To evaluate the safety of patients.

时间窗: Baseline, Day 28 (Week 4), Day 56 (Week 8)

Safety assessments will include recording of AE and well-being.

时间窗: Baseline, Day 28 (Week 4), Day 56 (Week 8)

次要结局

未报告次要终点

研究者

发起方
OVERSEAS HEALTH CARE PVT LTD.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Dimple Shah

Zyfis Lifesciences Private Limited

研究点 (4)

Loading locations...

相似试验

A study to check the safety of a tablet that... | 临床试验